Literature DB >> 8206409

Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma.

A Gadducci1, U Baicchi, R Marrai, B Del Bravo, P V Fosella, V Facchini.   

Abstract

The preoperative plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand Factor (vWF) were measured in 125 patients with ovarian masses undergoing laparotomy and in 88 healthy nonpregnant women as controls. FPA, DD, and vWF levels were significantly higher in the 58 patients with ovarian carcinoma than in the 67 patients with benign ovarian disease or controls. FPA and DD values were significantly higher in advanced (FIGO stage III-IV) than in early ovarian carcinoma. Among patients with advanced disease, FPA and DD levels correlated with none of the common clinicopathological prognostic variables; conversely, vWF values were related to FIGO stage (IV versus III, P < 0.02) and size of residual disease after initial surgery (> 2 cm versus < or = 2 cm, P < 0.05). In conclusion, increased fibrin production and degradation occur in patients with ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8206409     DOI: 10.1006/gyno.1994.1146

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

Review 1.  Role of von Willebrand factor levels in the prognosis of stage IV colorectal cancer: do we have enough evidence?

Authors:  I Gil-Bazo; J-A Díaz-González; J Rodríguez; J Cortés; E Calvo; J-A Páramo; J García-Foncillas
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

2.  Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer.

Authors:  Ignasio Gil-Bazo; Ignacio Gil Bazo; Victoria Catalán Goni; Victoria Catalán González; Alvaro Alonso Gutiérrez; Javier Rodríguez Rodríguez; José Antonio Páramo Fernández; Juan de la Cámara Gómez; José Luis Hernández Lizoain; Jesús García-Foncillas López
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

Review 3.  Pathogenesis of thrombosis in patients with malignancy.

Authors:  A Falanga; M B Donati
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

4.  Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer.

Authors:  Renyong Guo; Jiezuan Yang; Xia Liu; Jianping Wu; Yu Chen
Journal:  J Clin Lab Anal       Date:  2017-04-04       Impact factor: 2.352

Review 5.  Cancer-associated venous thromboembolism.

Authors:  Alok A Khorana; Nigel Mackman; Anna Falanga; Ingrid Pabinger; Simon Noble; Walter Ageno; Florian Moik; Agnes Y Y Lee
Journal:  Nat Rev Dis Primers       Date:  2022-02-17       Impact factor: 65.038

6.  Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma.

Authors:  Giovanni Marfia; Stefania Elena Navone; Claudia Fanizzi; Silvia Tabano; Chiara Pesenti; Loubna Abdel Hadi; Andrea Franzini; Manuela Caroli; Monica Miozzo; Laura Riboni; Paolo Rampini; Rolando Campanella
Journal:  Cancer Med       Date:  2016-05-28       Impact factor: 4.452

7.  Functional assessment of von Willebrand factor expression by cancer cells of non-endothelial origin.

Authors:  Anahita Mojiri; Konstantin Stoletov; Maria Areli Lorenzana Carrillo; Lian Willetts; Saket Jain; Roseline Godbout; Paul Jurasz; Consolato M Sergi; David D Eisenstat; John D Lewis; Nadia Jahroudi
Journal:  Oncotarget       Date:  2017-02-21

8.  Cancer cell-derived von Willebrand factor enhanced metastasis of gastric adenocarcinoma.

Authors:  Ai-Jun Yang; Min Wang; Yan Wang; Wei Cai; Qiang Li; Ting-Ting Zhao; Li-Han Zhang; Katie Houck; Xu Chen; Yan-Ling Jin; Ji-Ying Mu; Jing-Fei Dong; Min Li
Journal:  Oncogenesis       Date:  2018-01-24       Impact factor: 7.485

Review 9.  Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer.

Authors:  Chumnan Kietpeerakool; Amornrat Supoken; Malinee Laopaiboon; Pisake Lumbiganon
Journal:  Cochrane Database Syst Rev       Date:  2016-01-23

Review 10.  Surrogate markers in antiangiogenesis clinical trials.

Authors:  D W Davis; D J McConkey; J L Abbruzzese; R S Herbst
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.